Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Concetta Quintarelli

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Oncotarget|August 31, 2015
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogeneGiorgia Montano, Karina Vidovic, Chiara Palladino, et al.
Blood|July 20, 2007
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytesConcetta Quintarelli, Juan F Vera, Barbara Savoldo, et al.
Oncoimmunology|January 4, 2018
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical modelPaola Bocca, Emma Di Carlo, Ignazio Caruana, et al.
Haematologica|April 30, 2025
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19Simona Manni, Laura Iaffaldano, Marika Guercio, et al.
Cells|June 24, 2022
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune DeficienciesFederica Pulvirenti, Stefano Di Cecca, Matilde Sinibaldi, et al.
Leukemia Research|November 28, 2013
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemiaConcetta Quintarelli, Biagio De Angelis, Santa Errichiello, et al.
Frontiers in Immunology|April 8, 2017
Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive ImmunotherapyGiuseppina Li Pira, Stefano Di Cecca, Simone Biagini, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 5, 2009
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7Juan F Vera, Valentina Hoyos, Barbara Savoldo, et al.
Frontiers in Immunology|December 12, 2019
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T CellsVinicia A Polito, Rosaria Cristantielli, Gerrit Weber, et al.
Frontiers in Oncology|November 3, 2025
Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case reportValentina Di Ruscio, Alessia Carboni, Giada Del Baldo, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Oncotarget|August 31, 2015
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogeneGiorgia Montano, Karina Vidovic, Chiara Palladino, et al.
Blood|July 20, 2007
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytesConcetta Quintarelli, Juan F Vera, Barbara Savoldo, et al.
Oncoimmunology|January 4, 2018
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical modelPaola Bocca, Emma Di Carlo, Ignazio Caruana, et al.
Haematologica|April 30, 2025
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19Simona Manni, Laura Iaffaldano, Marika Guercio, et al.
Cells|June 24, 2022
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune DeficienciesFederica Pulvirenti, Stefano Di Cecca, Matilde Sinibaldi, et al.
Leukemia Research|November 28, 2013
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemiaConcetta Quintarelli, Biagio De Angelis, Santa Errichiello, et al.
Frontiers in Immunology|April 8, 2017
Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive ImmunotherapyGiuseppina Li Pira, Stefano Di Cecca, Simone Biagini, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 5, 2009
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7Juan F Vera, Valentina Hoyos, Barbara Savoldo, et al.
Frontiers in Immunology|December 12, 2019
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T CellsVinicia A Polito, Rosaria Cristantielli, Gerrit Weber, et al.
Frontiers in Oncology|November 3, 2025
Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case reportValentina Di Ruscio, Alessia Carboni, Giada Del Baldo, et al.
Pageof 9